Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESMO 2022 | Highlights in prostate cancer from ESMO

Fred Saad, MD, FRCS, University of Montreal Hospital Center, Montreal, Canada, shares his highlights in prostate cancer from the European Society for Medical Oncology (ESMO) 2022 Congress, including the Phase III PROpel trial (NCT03732820) of abiraterone and olaparib vs abiraterone and placebo as first-line therapy for patients with metastatic castration-resistant prostate cancer (mCRPC). The PROpel trial was one of the first positive studies with combination therapy beyond what is used in standard of care. In the hormone-sensitive setting, data was presented on the Phase III STAMPEDE (NCT00268476) trial, which demonstrated abiraterone with androgen deprivation therapy (ADT) does significantly better than ADT alone, as well as the combination of abiraterone with enzalutamide. However, the combination of abiraterone and enzalutamide provided no advantage over abiraterone alone. This interview took place at the European Society for Medical Oncology (ESMO) 2022 Congress in Paris, France.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.